Impressive long-term patient-reported outcomes (PROs) for RET-altered NSCLC, MTC, non-MTC thyroid cancer, and tumor agnostic (TA) patients from the LIBRETTO-001 trial were reported in a post hoc retrospective study by Raez et al. [83]. The gene discussed is RET; the disease is medullary thyroid gland carcinoma.